MediciNova, Inc. (MNOV) Analysts See $-0.09 EPS

September 22, 2017 - By Michael Collier

 MediciNova, Inc. (MNOV) Analysts See $ 0.09 EPS
Investors sentiment increased to 1.46 in Q2 2017. Its up 0.72, from 0.74 in 2017Q1. It improved, as 2 investors sold MediciNova, Inc. shares while 11 reduced holdings. 4 funds opened positions while 15 raised stakes. 7.81 million shares or 3.03% more from 7.58 million shares in 2017Q1 were reported.
Bankshares Of Mellon Corporation has invested 0% in MediciNova, Inc. (NASDAQ:MNOV). Schwab Charles Invest has invested 0% in MediciNova, Inc. (NASDAQ:MNOV). California-based Wells Fargo Mn has invested 0% in MediciNova, Inc. (NASDAQ:MNOV). Blackrock holds 2.11 million shares or 0% of its portfolio. Essex Woodlands Ventures stated it has 1.17M shares or 1.11% of all its holdings. Citigroup Inc has invested 0% in MediciNova, Inc. (NASDAQ:MNOV). Moreover, Geode Mgmt Ltd Liability Corporation has 0% invested in MediciNova, Inc. (NASDAQ:MNOV). State Street has invested 0% in MediciNova, Inc. (NASDAQ:MNOV). National Bank Of America De invested 0% of its portfolio in MediciNova, Inc. (NASDAQ:MNOV). State Common Retirement Fund holds 0% or 19,342 shares in its portfolio. Creative Planning owns 8,000 shares. Moreover, Proshare Ltd Liability Company has 0% invested in MediciNova, Inc. (NASDAQ:MNOV) for 20,621 shares. Ameritas Ptnrs holds 0% or 2,314 shares in its portfolio. Legal General Gru Public Ltd Company reported 8,651 shares. Deutsche Retail Bank Ag has 37,945 shares.

Since May 12, 2017, it had 2 buys, and 0 selling transactions for $140,480 activity.

Analysts await MediciNova, Inc. (NASDAQ:MNOV) to report earnings on October, 24. They expect $-0.09 earnings per share, down 12.50 % or $0.01 from last year’s $-0.08 per share. After $-0.08 actual earnings per share reported by MediciNova, Inc. for the previous quarter, Wall Street now forecasts 12.50 % negative EPS growth. The stock increased 3.89% or $0.22 during the last trading session, reaching $5.88. About 148,193 shares traded or 188.48% up from the average. MediciNova, Inc. (NASDAQ:MNOV) has declined 6.61% since September 22, 2016 and is downtrending. It has underperformed by 23.31% the S&P500.

Medicinova, Inc. is a biopharmaceutical company. The company has market cap of $20.67 million. The Firm focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. It currently has negative earnings. The Company’s pipeline includes MN-166 , MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).

More recent MediciNova, Inc. (NASDAQ:MNOV) news were published by: Seekingalpha.com which released: “MediciNova’s MN-166: Good Trial, But What About Generic Riluzole?” on March 29, 2017. Also Globenewswire.com published the news titled: “MediciNova Added to NASDAQ Biotechnology Index” on December 14, 2016. Globenewswire.com‘s news article titled: “MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical …” with publication date: September 19, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.